Compare Amgen, Inc. (AMGN) vs Ferrari NV (RACE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Ferrari NV — how do they compare? Amgen, Inc. trades at $415.25 (market cap $224.14B), while Ferrari NV trades at $406.38 (market cap $71.67B). The key difference: Amgen, Inc. is far larger — about 3.1× Ferrari NV's market cap, and Amgen, Inc. pays the higher dividend (2.43%). Which is the better fit depends on your goals.
| AMGN | RACE | |
|---|---|---|
Market Cap | $224.14B | $71.67B |
Sector | Health | Consumer Cyclical |
52-Week High | $417.20 | $504.09 |
52-Week Low | $271.18 | $314.63 |
Enterprise Value | $267.45B | $73.60B |
Dividend Yield | 2.43% | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $417.20, up 1.52% with strong technical momentum as price approaches resistance near $421. The company demonstrates robust fundamentals with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, marking the third consecutive quarterly beat. Revenue growth continues with 2025 revenue reaching $36.75 billion and 2026 projected at $38.1 billion, supported by strong performance from key products like Tezspire and Repatha.
Amgen presents a compelling growth story with raised 2026 guidance and strong product pipeline, though elevated valuation ratios (P/E 25.73, P/S 5.91) and high debt levels ($56.55 billion long-term debt) warrant caution. Analyst consensus remains bullish with 59% buy ratings and $394.69 price target, but current price trades above consensus target, suggesting near-term consolidation potential.
Ferrari (RACE) trades at $407.76, up 0.24% today, near its pivot point of $407 with bullish technical indicators. The stock shows strong fundamentals with a 22.25% net margin and consistent earnings beats, including Q2 2026 EPS of $2.99 versus $2.83 expected. Revenue growth is steady, reaching $7.15B in 2025, supported by high demand and personalization revenue.
Outlook remains positive with a consensus price target of $462.67, though elevated P/E of 37.93 poses valuation risk. Key opportunities include pricing power and EV expansion, while risks involve economic sensitivity and execution on new models. Analyst sentiment is strongly bullish with 72% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →
